Literature DB >> 11698814

Impact of Ménière's disease on quality of life.

J P Anderson1, J P Harris.   

Abstract

OBJECTIVE: To describe health-related quality of life among patients with Ménière's disease in whom conventional therapy failed and who requested further medical intervention. STUDY
DESIGN: Pretreatment interviews to establish baseline quality of life characteristics before medical intervention.
SETTING: Tertiary referral center. PATIENTS: 19 adult patients, 12 women and 7 men, whose ages ranged from 32 to 83 years.
INTERVENTIONS: Pretreatment baseline interviews. MAIN OUTCOME MEASURES: Quality of Well-being Scale, SF-12 Physical and SF-12 Mental scores, Center for Epidemiologic Studies-Depression Scale.
RESULTS: The Quality of Well-being score (0.561) indicated a loss of well-being from 1 to 0.561 = 43.9% in patients with Ménière's disease as compared with people with no symptoms and full functional status. The hypothesis that Quality of Well-being scores on days on which patients had symptoms characteristic of acute Ménière's disease episodes were lower than Quality of Well-being scores on days on which they did not report such symptoms was supported (p = 0.000). The reported SF-12 Physical mean score (38.9) was greater than 1 standard deviation below the general mean of 50, and the SF-12 Mental score (44.2) was 0.5 standard deviation below the general mean of 50. The Center for Epidemiologic Studies-Depression Scale score was 23, with a score 16 or greater indicating clinically significant depression.
CONCLUSIONS: The results suggest that the condition of patients with Ménière's disease may be measured by these instruments, that the instruments are in substantial agreement about the serious impairment in patients' quality of life, and that the days with acute episodes of Ménière's disease symptoms are significantly worse than the days without such symptoms. Treating physicians indicated surprise at the breadth and the level of debilitation characteristic of these patients with Ménière's disease.

Entities:  

Mesh:

Year:  2001        PMID: 11698814     DOI: 10.1097/00129492-200111000-00030

Source DB:  PubMed          Journal:  Otol Neurotol        ISSN: 1531-7129            Impact factor:   2.311


  22 in total

Review 1.  Vestibular dysfunction: prevalence, impact and need for targeted treatment.

Authors:  Yuri Agrawal; Bryan K Ward; Lloyd B Minor
Journal:  J Vestib Res       Date:  2013       Impact factor: 2.435

2.  Meniere's disease: Still a mystery disease with difficult differential diagnosis.

Authors:  A Vassiliou; P V Vlastarakos; P Maragoudakis; D Candiloros; T P Nikolopoulos
Journal:  Ann Indian Acad Neurol       Date:  2011-01       Impact factor: 1.383

3.  The Reliability and Validity of "Dokuz Eylül University Meniere's Disease Disability Scale".

Authors:  Başak Mutlu; Günay Kırkım; Serpil Mungan Durankaya; Selhan Gürkan; Tahsin Oğuz Başokçu; Enis Alpin Güneri
Journal:  J Int Adv Otol       Date:  2018-08       Impact factor: 1.017

4.  Sequential bilateral cochlear implantation in a patient with bilateral Ménière's disease.

Authors:  Laura K Holden; J Gail Neely; Brenda D Gotter; Karen M Mispagel; Jill B Firszt
Journal:  J Am Acad Audiol       Date:  2012-04       Impact factor: 1.664

5.  Vestibular and audiometric results after endolymphatic mastoid shunt surgery in patients with Menière's disease.

Authors:  Jennifer L Spiegel; Ivelina Stoycheva; Bernhard G Weiss; Mattis Bertlich; Tobias Rader; Martin Canis; Friedrich Ihler
Journal:  Eur Arch Otorhinolaryngol       Date:  2022-08-15       Impact factor: 3.236

6.  Patient Perceptions of Effectiveness in Treatments for Menière's Disease: a National Survey in Italy.

Authors:  Bryan Ward; Vincent Wettstein; John Golding; Giulia Corallo; Daniele Nuti; Franco Trabalzini; Marco Mandala
Journal:  J Int Adv Otol       Date:  2019-04       Impact factor: 1.017

Review 7.  Is gentamycin delivery via sustained-release vehicles a safe and effective treatment for refractory Meniere's disease? A critical analysis of published interventional studies.

Authors:  Petros V Vlastarakos; Emily Iacovou; Thomas P Nikolopoulos
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-09-13       Impact factor: 2.503

8.  Intratympanic (IT) Therapies for Menière's Disease: Some Consensus Among the Confusion.

Authors:  Desi P Schoo; Grace X Tan; Matthew R Ehrenburg; Seth E Pross; Bryan K Ward; John P Carey
Journal:  Curr Otorhinolaryngol Rep       Date:  2017-05-03

9.  The Weather and Ménière's Disease: A Longitudinal Analysis in the UK.

Authors:  Wiebke Schmidt; Christophe Sarran; Natalie Ronan; George Barrett; David J Whinney; Lora E Fleming; Nicholas J Osborne; Jessica Tyrrell
Journal:  Otol Neurotol       Date:  2017-02       Impact factor: 2.311

10.  Betahistine in the treatment of Ménière's disease.

Authors:  Michel Lacour; Paul H van de Heyning; Miroslav Novotny; Brahim Tighilet
Journal:  Neuropsychiatr Dis Treat       Date:  2007-08       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.